Key result
Home catecholamine support successfully bridges advanced heritable pulmonary arterial hypertension to sotatercept therapy.
Why the study?
Patients with advanced PAH requiring continuous catecholamine support have limited treatment options and poor prognosis, and home catecholamine therapy may improve quality of life until new treatments are available.
Case Report (n=1)
Home catecholamine support can serve as a viable bridging strategy to novel therapies like sotatercept for highly selected patients with advanced pulmonary arterial hypertension.
Sotatercept may facilitate catecholamine weaning in advanced PAH; hypothesis-generating case report requiring prospective trials before practice change.
Patients with advanced pulmonary arterial hypertension (PAH) who require continuous catecholamine support have limited treatment options and a poor prognosis.1 In selected patients, home catecholamine therapy may allow discharge from hospital and provide the psychological and physical comfort of remaining at home, thereby supporting quality of life. Sotatercept, an activin signaling inhibitor, has been reported to have favorable hemodynamic and functional effects in PAH.2,3 We report a patient with advanced heritable PAH who remained on home catecholamine support until sotatercept became available.
No takes yet. Share an insight, caveat, or question.
Yamazaki et al. (2026) conducted a case report in Advanced heritable pulmonary arterial hypertension (PAH) (n=1). Home catecholamine support as a bridge to sotatercept was evaluated. Home catecholamine support was utilized to allow hospital discharge and maintain a patient with advanced heritable pulmonary arterial hypertension until sotatercept therapy became available.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: